Core Viewpoint - Anixa Biosciences is advancing its breast cancer vaccine, with additional data from its Phase 1 clinical trial to be presented at the SITC 39th Annual Meeting, highlighting the collaboration with Cleveland Clinic and funding from the U.S. Department of Defense [1][5]. Group 1: Clinical Trial Details - The Phase 1 trial focuses on the alpha-lactalbumin vaccine for high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC [2][3]. - Initial Phase 1 data presented in December 2023 indicated no safety concerns and observed immune responses in a majority of patients [4]. Group 2: Vaccine Technology - The breast cancer vaccine utilizes α-lactalbumin, a protein that is present in certain breast cancers but absent in normal aging tissues post-lactation, to activate the immune system against emerging tumors [3][6]. - The vaccine includes an adjuvant to enhance the innate immune response, aiming to prevent tumor growth [3]. Group 3: Company Background - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program and various cancer vaccines [7]. - The company partners with renowned research institutions to develop and commercialize innovative cancer therapies [7].

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: | --- | --- ...

Core Insights - Adagene Inc. is set to present two posters at the SITC 39th Annual Meeting, focusing on its lead clinical program, ADG126, a masked anti-CTLA-4 SAFEbody, and its combination with anti-PD-1 therapy [1] Company Overview - Adagene Inc. is a clinical-stage biotechnology company specializing in novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence to meet unmet patient needs [2] - The company has established strategic collaborations leveraging its SAFEbody precision masking technology [2] Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, aimed at addressing safety and tolerability challenges in antibody therapeutics [3] - The SAFEbody technology allows for tumor-specific targeting while minimizing off-tumor toxicity, enhancing the therapeutic index of antibody treatments [3] Clinical Development - The lead clinical program, ADG126 (muzastotug), targets a unique epitope of CTLA-4 in regulatory T cells within the tumor microenvironment and is currently in phase 1b/2 studies in combination with anti-PD-1 therapy for Metastatic Microsatellite-stable Colorectal Cancer [4]

Submitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants on Tuesday, November 5th at 9:00 AM U.S. ET Presentations of Beyond Cancer's two full posters will take place on November 8th and 9th at the SITC Annual Meeting; ePublications of the posters will be available November 7th Therapeutic efficacy of Low Volume (<1L) UNO demonstrated in both mice and rat tumor models HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotec ...

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinicalstage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new pr ...

Core Insights - Medicenna Therapeutics Corp. will present updated clinical results from the ongoing Phase 1/2 ABILITY-1 study of MDNA11, a long-acting IL-2 super-agonist, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] - The company will also showcase preclinical data on MDNA113, a novel bifunctional anti-PD1-IL-2 Superkine, and its IL-2 agonists in glioblastoma [1][2] Presentation Details - The poster presentations will include: - Results from the ABILITY-1 monotherapy dose escalation and ongoing monotherapy expansion with MDNA11 [3] - MDNA113's mechanism as a conditionally activatable anti-PD1-IL-2 Superkine [3] - Stimulation of IL-2 signaling in glioblastomas using selective IL-2R agonists [3] About MDNA11 - MDNA11 is designed to preferentially activate immune effector cells while minimizing stimulation of immunosuppressive Tregs, achieved through specific mutations and fusion to a recombinant human albumin scaffold [4] - It is currently being evaluated in the Phase 1/2 ABILITY-1 study as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®) [4] About the ABILITY-1 Study - The ABILITY-1 study is a global, multi-center, open-label study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of MDNA11 [5][6] - The study includes a combination dose escalation with approximately 6-12 patients expected to be enrolled [5] About MDNA113 - MDNA113 is a first-in-class tumor-targeted bifunctional anti-PD1-IL-2 Superkine with high affinity for IL-13Rα2, which is overexpressed in various solid tumors [7] - The expression of IL-13Rα2 is associated with poor clinical outcomes in multiple tumor types, highlighting the potential significance of MDNA113 in cancer therapy [7] About Medicenna Therapeutics - Medicenna is focused on developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, including the long-acting IL-2 Superkine MDNA11 [8] - The company has also developed bizaxofusp, which has been studied in clinical trials for recurrent glioblastoma and has received FastTrack and Orphan Drug status from the FDA [8]

PHILADELPHIA, Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024. Details on the poster presentations at SITC 2024 are below: Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepato ...

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Office ...

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTORENHANCED CELL ENGA ...

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company's Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024). The conference will be held in H ...